Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck

Michael P. Stevens MD, MPH1, Payal K. Patel MD, MPH2 and Priya Nori MD3
1Healthcare Infection Prevention Program, Virginia Commonwealth University Health System, Richmond, Virginia, 2Infectious Diseases Section, Ann Arbor VA Medical Center, Ann Arbor, Michigan and 3Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

To the Editor—To our knowledge, no formal recommendations exist for the inclusion of antimicrobial stewardship programs (ASPs) in disaster planning or emergency response preparedness efforts.1 A PubMed search utilizing the search terms “antimicrobial stewardship” AND “disaster planning” was performed on March 4, 2020, and yielded no results. ASPs are now ubiquitous. They often include pharmacists and physicians with advanced infectious diseases training, and they are a valuable part of hospital safety and quality programs. In some hospitals, compartmentalization of stewardship and epidemiology functions have developed over time to meet distinct institutional needs. However, domains should coalesce for purposes of emergency preparedness. The current SARS-CoV-2/COVID-19 outbreak highlights numerous opportunities where ASPs can support emerging pathogen response and planning efforts.

An informal Twitter poll was initiated on March 1, 2020, asking the infectious diseases and antimicrobial stewardship communities whether ASPs at their health systems had been involved in SARS-CoV-2/COVID-19 outbreak response or preparation. This yielded 254 responses: 30% noted direct involvement, 28% indicated indirect involvement, and 39% indicated no involvement in emergency response efforts or planning. Although formalized study is needed, real-time insights from the community provided valuable information. We identified multiple potential areas where ASPs can support emergency response efforts, and these are summarized in Figure 1.

ASPs that are integrated with hospital infection prevention programs have an advantage in response efforts to emerging pathogens in that (1) they are likely to have pre-existing infection prevention skills and experience, (2) they are likely to be involved in response efforts early, and (3) they will have access to and influence with key stakeholders. Because ASPs and infection prevention programs share similar technology infrastructure, data, and metrics, program integration has many advantages.2 Response efforts to novel respiratory viruses like SARS-CoV-2/COVID-19 represent an opportunity for programs to formally integrate, to develop cross-cover capabilities, and to create shared leadership opportunities.

ASPs can support SARS-CoV-2/COVID-19 response efforts in numerous ways within the context of their normal daily activities. A core component of antimicrobial stewardship includes postprescriptive review with feedback to providers.3 In this way, an ASP skill set can theoretically assist with early identification of potential cases. This approach may be especially useful in situations in which the definition of a person under investigation is fluid because traditional epidemiologic efforts usually focus on identifying patients at the point of entry into health systems. ASPs often coordinate with microbiology laboratories for real-time interpretation and action involving upper respiratory PCR test results. They can support SARS-CoV-2/COVID-19 evaluation efforts in this fashion as well. Novel respiratory virus outbreaks associated with secondary bacterial pneumonias and acute respiratory distress syndrome (ARDS) provide an opportunity for ASPs to monitor compliance with guideline-concordant therapy; severe COVID-19 cases have been treated with broad-spectrum antibiotics.4

Additionally, ASPs can help in the development of local treatment protocols involving repurposed antivirals; they can monitor and manage drug shortages due to supply chain interruptions5; and they can assist frontline providers with expanded access investigational new drug applications (eINDs) and local institutional review board procedures for investigational agents.

ASPs are now mandated in the United States and are often multidisciplinary. The Joint Commission accreditation standard for ASPs includes, when available, an infectious diseases physician, pharmacist, infection preventionist, and other practitioners.6 ASP physician and pharmacy leaders often have specialized infectious diseases training.5 Leveraging these resources for planning and response efforts for emerging pathogens is critical and can strengthen and sustain collaborative relationships.

We recommend that hospital epidemiology programs strongly consider integrating their ASP colleagues into disaster preparedness plans as well as identify a more formal role for stewards in their operations beyond the current COVID-19 outbreak.

Acknowledgments.

Financial support. No financial support was provided relevant to this article.

© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. Banach DB, Johnston BL, Al-Zubeidi D, et al. Outbreak response and incident management: SHEA guidance and resources for healthcare epidemiologists in United States acute-care hospitals. Infect Control Hosp Epidemiol 2017;38:1393–1419.

2. Abbas S, Stevens MP. The role of the hospital epidemiologist in antibiotic stewardship. Med Clin North Am 2018;102:873–882.

3. Doernberg SB, Abbo LM, Burdette SD, et al. Essential resources and strategies for antibiotic stewardship programs in the acute care setting. Clin Infect Dis 2018;67:1168–1174.

4. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020. doi:10.1001/jama.2020.3204

5. Coronavirus (COVID-19) Supply Chain Update. US Food and Drug Administration website. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-supply-chain-update. Accessed March 4, 2020.

6. Approved: new antimicrobial stewardship standard. The Joint Commission website. https://www.jointcommission.org/-/media/enterprise/tjc/imported-resource-assets/documents/new_antimicrobial_stewardship_standard.pdf?db=web&hash=69307456CCE435B13485439C27FA7D76. Published July 2015. Accessed March 5, 2020.

Protecting Chinese healthcare workers while combating the 2019 novel coronavirus

Pengcheng Zhou MD1, Zebing Huang MD2, Yinzong Xiao MD2,3, Xun Huang MD1 and Xue-Gong Fan MD2

1Infection Control Centre, Xiangya Hospital, Central South University, Changsha, China, 2Hunan Key Laboratory of Viral Hepatitis & Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China and 3Burnet Institute, St Vincent’s Hospital Melbourne, and University of Melbourne, Melbourne, Australia

To the Editor—Hospital-associated transmission is an important route of spreading the 2019 novel coronavirus SARS-CoV-2 and pneumonia (coronavirus disease 2019, COVID-19).1 Healthcare workers (HCWs) are at high risk while combating COVID-19 at the very front line, and nosocomial outbreaks among HCWs are not unusual in similar settings. The 2003 severe acute respiratory syndrome (SARS) outbreak led to >966 HCW infections with 1.4% deaths in mainland China.2 As of February 11, 2020, 3,019 HCWs might have been infected with SARS-CoV-2 in China, and 1,716 HCW cases of COVID-19 have been confirmed by nucleic acid testing.3 At least 6 HCWs have died, including the famous whistleblower Dr Li Wenliang. In view of this severe situation, we are recommending urgent interventions to help to protect HCWs.

A few aspects of COVID-19 have created a more severe situation than expected among HCWs. First, many infected individuals present with a typical symptoms, such as gastrointestinal symptoms and fatigue, or are asymptomatic.4 This situation may lead to a lack of recognition of the infection while patients are highly